Diagnostic ToolboxUnderstand cancer cells like never before
Our cancer-specific rare-cell tests provide physicians with improved clinical insights into prostate cancer patients with unclear diagnostic findings. Our first test, X-ZELL Prostate™, is now officially avaialble in Thailand.
More than 50% of patients who receive a painful tissue biopsy turn out not to have cancer, and in up to 25% of cases, biopsies fail to detect cancer although it is there (false negatives). As such, X-ZELL Prostate™ can help avoid unnecessary biopsies and, even more importantly, correct decisions based on false negative biopsies.
- Patients with negative biopsy but persistent clinical suspicion of prostate cancer
Presence of CTC can help to decide about urgency of follow-up or the necessity of additional imaging
- Patients with unclear MRI outcome
Presence of CTC can help to decide about urgency of follow-up
- Patients who decline prostate biopsy
Obtain additional evidence to convince patients about the need for prostate biopsy
Use the contact form below to find out when X-ZELL Prostate™ goes on sale in your region.
X-ZELL’s rare-cell detection and characterization processes can be applied to a broad range of clinical research questions – from minimal residual disease monitoring in solid tissue tumours as well as hematologic malignancy, companion diagnostics to diagnostic decision-making in a wide range of malignancies. X-ZELL is able to process heparinized blood samples and report results in as little as four business days, covering the complete process of rare-cell isolation, cryofixation and Cryoimmunostaining™ as well as HD image acquisition and image analysis.
Use the contact form below to book a consultation.
Stop optimizing, start discovering: Achieve unprecedented multiplexing of immunostaining on standard laboratory slides using commercially available fluorophore-conjugated antibodies. Understand your cells at the single cell level without effort.
Use the contact form below to book a prototype demonstration.
MORE TO COME
Additional cancer-specific rare-cell tests are set to roll out in 2018, starting with X-ZELL Breast™.
Immunostaining of cells on laboratory slides is the backbone of pathology. Single cell detection and analysis, however, have long been hampered by a severe lack of multiplexing capability. Our Cryoimmunostaining™ platform – comprising the X-ZELL Fixation Station™ and the X-ZELL Cryoimmunostainer™ – offers the disruptive technology to change that.
- 10-channel multiplexing
- Staining with commercially available fluorophore-conjugated antibodies
- No spectral unmixing required
- Rapid 3h workflow
- CE-IVD & USFDA medical device certification
Contact X-ZELL to find out more.
Get in Touch
Use the form below to contact us for more information.